Alabama health officials have unanimously withdrawn the state’s objection to placing qualifying medical marijuana products in Schedule III, ending a temporary state-level hold that officials imposed while they examined how the federal change would interact with Alabama law. The State Committee of Public Health voted September 17 to withdraw the objection after the Alabama Department of Public Health concluded that concerns involving pharmacies, patients and the state’s newly operational medical cannabis system had been adequately addressed. State Health Officer Dr. Scott Harris said officials did not identify problems serious enough to justify continuing the objection.
The timing is particularly notable because Alabama’s medical cannabis program is finally moving from years of licensing disputes and litigation into actual patient access. The state’s first dispensary opened in Montgomery on June 4, 2026, followed by a Talladega location on August 28 and a third dispensary in Athens on September 14. Additional sites are expected as licensed operators become operational. Alabama’s decision on Schedule III therefore comes just as the state is beginning to experience the practical realities of the medical marijuana system lawmakers authorized more than five years ago.
Alabama’s Original Objection Was a Procedural Delay
The state’s May objection was not a declaration that Alabama intended to permanently reject Schedule III. Under Alabama Code §20-2-20(c), when the federal government schedules, reschedules or removes a controlled substance, Alabama generally follows the federal action after 30 days. However, the State Committee of Public Health can object during that period, temporarily stopping the parallel state change while officials investigate the consequences and hold a public hearing.
That is exactly what Alabama officials did after the Justice Department issued its April 2026 marijuana order. In its formal objection, the committee emphasized that Alabama had only recently established a separate medical cannabis system under the Darren Wesley “Ato” Hall Compassion Act. Officials said they needed additional time to determine whether federal rescheduling would interfere with the framework created by the Legislature. The committee explicitly said it would reconsider its position after consulting affected government agencies and receiving testimony at a public hearing.
The September decision therefore represents the completion of that review rather than an abrupt reversal of state cannabis policy. Harris said the department’s legal team had resolved concerns involving pharmacies and people obtaining medical cannabis. After that analysis, the committee voted unanimously to withdraw the objection.
The Federal Schedule III Change Is Narrower Than Full Marijuana Rescheduling
One of the most important details surrounding the Alabama decision is that the federal government has not yet placed all marijuana nationwide into Schedule III. On April 23, the Justice Department and DEA issued a final order placing two specific categories into Schedule III: FDA-approved drug products containing marijuana and marijuana products covered by qualifying state-issued medical marijuana licenses. DOJ said the change was intended to recognize regulated state medical programs while maintaining federal controlled-substance requirements.
That distinction matters for Alabama. The April rule creates a Schedule III framework for qualifying medical marijuana activity; it does not legalize recreational marijuana, authorize interstate recreational cannabis sales or automatically make every cannabis product federally lawful. DEA registration and other federal controls remain relevant to businesses seeking to operate within the new framework. Adult-use marijuana outside the scope of qualifying medical licenses is not covered by the April medical-marijuana order.
A separate federal proceeding is considering whether marijuana generally should be transferred from Schedule I to Schedule III. DEA held an 11-day administrative hearing during June and July, and the agency’s current rescheduling page continues to list that proceeding separately from the already-effective medical marijuana rule. As of September 20, the broader proceeding has not produced a final nationwide order.
Public Hearing Revealed a Broader Debate Over Marijuana
Alabama held its required public hearing on July 22 in Montgomery. Several conservative activists urged the state to maintain its objection, raising concerns involving youth exposure, mental health and what they viewed as insufficient evidence supporting cannabis as medicine. Lori Herring of Eagle Forum of Alabama asked the state to retain the objection and argued that Alabama should maintain stricter standards than the federal government.
Joey Robertson, president and CEO of Wagon Trail Med-Serv, was reported as the only speaker at the hearing explicitly supporting the rescheduling change. He argued that Alabama had already established a tightly controlled medical program and that refusing to align the drug’s classification with the federal medical framework could undermine trust among patients, physicians and state regulators.
Harris later said much of the testimony addressed whether people supported or opposed medical marijuana generally rather than the narrower issue the department was examining—what practical consequences would result from changing the schedule. After the department’s lawyers reviewed those consequences, Harris said he saw no unresolved issue requiring Alabama to continue blocking the state-level change.
Alabama’s Medical Cannabis Market Is Finally Becoming Real
The decision arrives at a major transition point for Alabama cannabis policy. Lawmakers approved the Compassion Act in 2021, but patients then endured years of delays as licensing decisions generated administrative disputes and lawsuits. Commercial medical cannabis did not finally reach patients until June 2026. The Alabama Medical Cannabis Commission now lists operational dispensaries in Montgomery, Talladega and Athens, with locations in additional cities expected as approved companies begin operating.
The eventual market could be considerably larger. Alabama permits as many as four standalone dispensary licensees, each generally capable of operating up to three dispensing sites, while as many as five integrated-facility licensees may operate up to five locations apiece. Depending on licensing outcomes, the state could ultimately approach 40 medical cannabis dispensing locations. Current or planned dispensary markets include Birmingham, Bessemer, Montgomery, Talladega, Athens, Attalla, Oxford, Daphne and Mobile.
Alabama’s program remains among the more restrictive medical cannabis systems in the country. Patients must be Alabama residents, have an eligible medical condition, receive a recommendation from an approved physician and register with the Medical Cannabis Commission. Permitted products include tablets, capsules, tinctures, certain gelatinous products, topical preparations, suppositories, transdermal patches and specified inhaler or nebulizer preparations. Raw cannabis flower for smoking and conventional vaping products are prohibited.
Schedule III Does Not Replace Alabama’s Medical Marijuana Law
Harris emphasized that Alabama’s existing program did not depend on the cannabis being moved out of Schedule I under Alabama’s controlled-substance regulations. The Legislature wrote the Compassion Act to provide specific legal protections for authorized patients, caregivers and licensed businesses. That is why legal medical cannabis sales were able to begin even while the state’s general controlled-substance schedule still classified marijuana under Schedule I.
Withdrawing the objection therefore does not dramatically expand who can buy medical cannabis in Alabama. It does not add qualifying conditions, authorize recreational possession, allow home cultivation or suddenly permit smokable marijuana. Patient eligibility and permitted product forms continue to be governed primarily by the medical cannabis statute and regulations administered by the Alabama Medical Cannabis Commission and Board of Medical Examiners.
What changes is the underlying controlled-substance classification for cannabis falling within the federal medical-marijuana rule. That creates greater consistency between Alabama and federal scheduling rules precisely as Alabama’s licensed medical market begins operating.
Research and Federal Tax Treatment Could Become Important
One of the federal government’s stated reasons for the April action was to make legitimate cannabis research easier. DOJ said the Schedule III framework was intended to improve scientists’ ability to investigate medical marijuana’s safety and efficacy while retaining controlled-substance oversight. DEA has also created a registration pathway specifically for state-licensed medical marijuana dispensaries and other qualifying operators.
Schedule III could also have major tax consequences because Internal Revenue Code §280E applies to businesses trafficking in Schedule I or Schedule II controlled substances. Cannabis companies have historically been unable to deduct many ordinary operating expenses because marijuana was federally classified in Schedule I. Public cannabis companies have begun taking the position that qualifying medical operations covered by the April Schedule III order are no longer subject to §280E for activity after the rule became effective, although federal tax guidance and questions involving mixed medical and recreational operations remain unresolved. Curaleaf, for example, disclosed to the SEC that it stopped applying §280E to qualifying state-licensed medical cannabis activity after April 23 while continuing to recognize uncertainty involving implementation.
That distinction could matter eventually to Alabama businesses because the state is medical-only. But Schedule III should not be interpreted as automatically freeing every Alabama cannabis company from federal regulation. Businesses operating within the federal framework may still need DEA registration and must comply with other applicable federal requirements.
Alabama’s Decision Does Not Settle the Debate Over Cannabis Risks
The committee’s unanimous vote should also not be interpreted as a finding that marijuana is harmless. Schedule III substances remain controlled drugs, and the federal classification itself recognizes abuse and dependence risks. Alabama continues to impose significant safeguards on medical cannabis, including physician certification, restricted product types and rules governing patient eligibility.
Opponents of rescheduling continue to argue that loosening marijuana’s classification could normalize cannabis use and understate risks involving adolescents, psychiatric outcomes and high-THC products. Supporters counter that maintaining Schedule I treatment for state-regulated medical products is increasingly difficult to reconcile with widespread medical use and limits research capable of answering those safety questions. Alabama’s July hearing reflected both sides of that larger debate, even though state officials ultimately characterized their own scheduling decision as a technical question of implementation rather than an endorsement of broader legalization.
Alabama Is Moving From Cannabis Litigation to Cannabis Implementation
For years, most major Alabama medical marijuana news concerned licensing disputes, court cases and repeated delays. The situation in September 2026 looks different. Patients can now purchase regulated products at three operating dispensaries, additional locations are preparing to open, and the state has begun moving toward alignment with the new federal medical-marijuana classification.
The September 17 vote is therefore significant less because Alabama has suddenly embraced broad cannabis legalization—it has not—and more because the state has decided that maintaining a special objection to the federal medical Schedule III framework is no longer necessary. The federal government’s broader proposal to reschedule marijuana nationwide remains unresolved, while Alabama’s tightly regulated medical program will continue operating under its own patient, product and licensing restrictions.
For Alabama patients and medical cannabis businesses, the practical story is increasingly about implementation rather than whether the program will ever launch. After a five-year wait, legal medical cannabis is finally being sold in the state. Alabama’s withdrawal of its Schedule III objection removes another layer of regulatory uncertainty just as that market begins to develop.
